BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32364660)

  • 1. The role of NAT2 polymorphism and methylation in anti-tuberculosis drug-induced liver injury in Mongolian tuberculosis patients.
    Zhang D; Hao J; Hou R; Yu Y; Hu B; Wei L
    J Clin Pharm Ther; 2020 Jun; 45(3):561-569. PubMed ID: 32364660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
    Xiang Y; Ma L; Wu W; Liu W; Li Y; Zhu X; Wang Q; Ma J; Cao M; Wang Q; Yao X; Yang L; Wubuli A; Merle C; Milligan P; Mao Y; Gu J; Xin X
    PLoS One; 2014; 9(1):e85905. PubMed ID: 24465778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
    Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
    Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.
    Shi J; Xie M; Wang J; Xu Y; Liu X
    Pharmacogenomics; 2015 Dec; 16(18):2083-97. PubMed ID: 26616266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis.
    Sun F; Chen Y; Xiang Y; Zhan S
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):994-1002. PubMed ID: 18713495
    [TBL] [Abstract][Full Text] [Related]  

  • 6.  NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population.
    Lv X; Tang S; Xia Y; Zhang Y; Wu S; Yang Z; Li X; Tu D; Chen Y; Deng P; Ma Y; Chen D; Chen R; Zhan S
    Ann Hepatol; 2012; 11(5):700-7. PubMed ID: 22947533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.
    Leiro-Fernandez V; Valverde D; Vázquez-Gallardo R; Botana-Rial M; Constenla L; Agúndez JA; Fernández-Villar A
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1403-8. PubMed ID: 22283902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
    Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population.
    Mishra S; Daschakraborty S; Shukla P; Kapoor P; Aggarwal R
    Natl Med J India; 2013; 26(5):260-5. PubMed ID: 25017831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
    Teixeira RL; Morato RG; Cabello PH; Muniz LM; Moreira Ada S; Kritski AL; Mello FC; Suffys PN; Miranda AB; Santos AR
    Mem Inst Oswaldo Cruz; 2011 Sep; 106(6):716-24. PubMed ID: 22012226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
    Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
    J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of LEPR polymorphisms with predisposition and inflammatory response in anti-tuberculosis drug-induced liver injury: A pilot prospective investigation in Western Chinese Han population.
    Zhao Z; Peng W; Zhou J; Zhou Y; Liu T; Bai H; Wu Q; Song J; Wu L; Song X; Ying B
    Infect Genet Evol; 2019 Nov; 75():103970. PubMed ID: 31325611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The associations of polymorphism of N-acetyltransferase 2 gene is associated with antituberculosis drug-induced hepatotoxicity in tuberculosis patients].
    An HR; Wu XQ; Wang ZY; Liang Y; Zhang JX
    Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Jan; 45(1):36-40. PubMed ID: 21418817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.
    Cai Y; Yi J; Zhou C; Shen X
    PLoS One; 2012; 7(10):e47769. PubMed ID: 23082213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.
    Ng CS; Hasnat A; Al Maruf A; Ahmed MU; Pirmohamed M; Day CP; Aithal GP; Daly AK
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1079-86. PubMed ID: 24888881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
    Yuliwulandari R; Prayuni K; Susilowati RW; M Sofro AS; Tokunaga K; Shin JG
    Pharmacogenomics; 2019 Dec; 20(18):1303-1311. PubMed ID: 31699005
    [No Abstract]   [Full Text] [Related]  

  • 18. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study.
    Chen R; Zhang Y; Tang S; Lv X; Wu S; Sun F; Xia Y; Zhan SY
    J Clin Pharm Ther; 2015 Feb; 40(1):110-5. PubMed ID: 25250564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.
    Chen G; Wu SQ; Feng M; Wang Y; Wu JC; Ji GY; Zhang MM; Liu QQ; He JQ
    Int J Immunopathol Pharmacol; 2017 Dec; 30(4):434-438. PubMed ID: 28934901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.
    Bozok Cetintaş V; Erer OF; Kosova B; Ozdemir I; Topçuoğlu N; Aktoğu S; Eroğlu Z
    Tuberk Toraks; 2008; 56(1):81-6. PubMed ID: 18330759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.